ADVANCED BREAST CANCER

This early-stage study tests a new drug called BMS-986500 in people with advanced solid tumors or breast cancer that has stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 234 adults will take part, receiving the drug alone …

This study looks at how well and how safely the drug dalpiciclib works for people with a certain type of advanced breast cancer (HR+/HER2-). About 103 participants will take the drug, and researchers will track how long the cancer stays under control and any side effects. The goa…

This study compares taking pyrotinib every day versus taking it on an intermittent schedule for people with HER2-positive advanced breast cancer. About 186 adults whose cancer has spread or cannot be removed by surgery will participate. The goal is to see if intermittent dosing w…

This early-phase study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, colorectal, or lung cancer) that have not responded to standard treatments. The drug works by blocking a key cancer growth signal (PI3Kα:RAS). The main goals are to find a safe …

This study tests a new drug called QL1706 in people with a certain type of advanced breast cancer (HR+/HER2-). The goal is to see if it can slow down the cancer's growth. About 123 women will take part, and the study will compare the drug to standard treatment.

This study tests whether adding the drug capivasertib to standard hormone therapy helps people with advanced HR+/HER2- breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib pl…

This early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check the drug's safety, find the right dose, and se…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy can shrink tumors or slow cancer growth in people with advanced HER2-negative breast cancer that has stopped responding to previous treatments. About 92 adults will receive the combination…

This study tests a new drug, ETX-636, for people with advanced solid tumors (like breast cancer) that have a specific genetic change called PIK3CA. The drug is designed to block a faulty protein that helps cancer grow. The trial will first test the drug alone, then in combination…

This study tests a treatment called TIL therapy for people with advanced breast cancer who have run out of standard options. Doctors take immune cells from a patient's tumor, grow them in a lab, and put them back into the body after a short chemotherapy. The goal is to shrink tum…

This early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced HR+/HER2- breast cancer or other solid tumors that have spread. The main goal is to find the safest and most effective dose, either…

This study tests whether a new drug combination (saruparib plus camizestrant) works better than current standard treatments for advanced breast cancer that is hormone receptor positive and HER2-negative in people with BRCA1, BRCA2, or PALB2 mutations. About 500 adults with advanc…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. The study includes adults with certain cancers and children aged 12…

This study tests whether adding trastuzumab (a targeted therapy) to eribulin (a chemotherapy drug) works better than eribulin alone for people with advanced HER2-positive breast cancer that has not responded to at least two prior treatments. About 180 adults with metastatic or in…

This study tests whether certain drug combinations can help people with advanced ER+/HER2- breast cancer whose disease has stopped responding to standard CDK4/6 inhibitor pills. About 135 postmenopausal women will receive one of several treatment arms based on their tumor's genet…

This study tests a two-step treatment plan for 45 women with a certain type of advanced breast cancer (HR+/HER2-low). First, they receive a targeted drug called trastuzumab rezetecan for several months. Then, they switch to a combination of a CDK4/6 inhibitor and hormone therapy.…

This study tests a new drug, OP-1250, against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can delay cancer growth better than standard care. About 510 adults whose…

This study tests a new drug called patritumab deruxtecan in people with advanced breast cancer that is hormone-receptor positive and no longer responds to hormone therapy or CDK4/6 inhibitors. About 99 participants will receive the drug every three weeks to see if it shrinks tumo…

This study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…

This study tests whether combining two experimental drugs, MHB036C and MHB039A, can shrink or control advanced breast cancer and other solid tumors that have spread. About 210 adults aged 18 to 75 with measurable tumors will receive the combination. The goal is to see if the trea…

This study is testing a drug called trastuzumab deruxtecan in 118 adults with advanced breast cancer. The goal is to see how long the drug can keep the cancer from growing and to check for side effects. Participants will receive the drug as part of their normal care, and the stud…

This study tests a drug called Disitamab vedotin in 36 women with advanced breast cancer that has low HER2 levels and has spread. Participants have had only one previous chemotherapy and no prior antibody-drug treatments. The goal is to see if the drug can shrink tumors and contr…

This study tests whether adding everolimus to elacestrant works better than elacestrant alone for people with a certain type of advanced breast cancer (ER+/HER2- with an ESR1 mutation). About 240 adults whose cancer has worsened after standard hormone therapy and CDK4/6 inhibitor…

This study looks at whether giving antibody-drug conjugates (ADCs) a second time is safe and effective for people with advanced breast cancer that has spread. About 160 adults who have already received ADCs will be enrolled. The goal is to see if the tumors shrink or stop growing…

This study tests whether the drug sacituzumab govitecan (SG) can still shrink tumors in people with a certain type of advanced breast cancer (HR+/HER2 low) who have already received a similar drug called T-DXd. About 75 adults will receive SG at its standard dose. The goal is to …

This study tests whether a new drug (RLY-2608) combined with fulvestrant works better than another approved combination (capivasertib + fulvestrant) for people with advanced or metastatic HR+/HER2- breast cancer that has a PIK3CA mutation. About 540 adults whose cancer worsened a…

This study tests a new cancer pill (PF-08032562) in people with advanced breast or colorectal cancer that has spread. The goal is to find the safest dose and see how well it works alone or with other treatments. About 260 adults will take the pill daily in 28-day cycles, with som…

This study compares a combination of two chemotherapy drugs (capecitabine and cyclophosphamide) against the doctor's choice of treatment as maintenance therapy for people with advanced breast cancer whose disease is currently under control. The goal is to see if the drug combo ca…

This early study tests a new drug called MEN2312 in people with advanced breast cancer that has spread and is not curable. The goal is to find a safe dose and see if it shrinks tumors or slows the cancer. About 240 adults will take the drug alone or with other treatments.

This early-stage study tests an experimental oral drug called BBI-940 in adults with advanced or metastatic breast cancer. The drug works by breaking down a protein that helps cancer cells grow. It is given alone or with another drug (fulvestrant). The main goals are to check saf…

This early-stage study tests a new drug, RLY-2608, designed to block a faulty protein in cancer cells with a specific gene change (PIK3CA mutation). It is for adults with advanced solid tumors or certain breast cancers that have not responded to other treatments. The study will t…

This study tests a drug called trastuzumab deruxtecan (T-DXd) against the usual treatment (a CDK4/6 inhibitor plus hormone therapy) for people with advanced breast cancer that is hormone receptor-positive and HER2-low or ultralow. The trial includes 200 adults whose cancer has a …

This study tests whether a digital health platform, which includes a symptom-tracking app and a nurse-led phone program, can help cancer patients better manage chemotherapy side effects. About 414 adults with early or advanced stomach, lung, breast, or colon cancer will participa…

This study tests a new program called ENGAGE, delivered via telehealth, to help people with stage IV breast, prostate, lung, or colorectal cancer better manage symptoms like pain, fatigue, and distress. About 190 participants will be randomly assigned to either ENGAGE or standard…

This study explores whether regular video or phone check-ins between patients with advanced breast cancer, their caregivers, and their cancer care teams can improve the hospice experience. About 200 participants receiving in-home hospice care in Massachusetts will take part. The …

This study enrolls 400 adults with advanced breast, lung, stomach, or bladder cancer who are receiving antibody-drug conjugates (ADCs), a type of targeted therapy. Researchers will compare tumor samples taken before treatment and after the cancer progresses to identify genetic or…